1、novotech-AUGUST 13,2024Pancreatic Cancer-Global Clinical Trial Landscape(2024)The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other elec

2、tronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or inte

3、llectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?Asia had the highest inc

4、idence cases and accounted for nearly 45%of the global incidence cases of PCEurope had the second highest incidence,with over 146,000 casesNorth-America had more than 67,000 cases,followed by rest of the world(ROW)Countries like United States,Mainland China,Australia,Spain,and South Korea emerged as

5、 top locations for conducting trialsAsia-Pacific showed faster recruitment durations and patient recruitment ratesPANCREATIC CANCERTRIAL CONTRIBUTIONSThe PC treatment market ofers diverse products by compa-nies including Astellas Pharma Inc.,Bristol Myers Squibb Co.and GemVax&Kael Co.LtdMultiple ong

6、oing Phase III trials demonstrate contin-ued eforts to enhance PC treatment through antibody,small molecule,and proteinPANCREATIC CANCER(PC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)5%ROW38%NORTH AMERICA57%ASIA-PACIFIC&EUROPEPANCREATIC CANCER12thMOSTDIAGNOSEDCANCER6thLEADING CAUSE OF CANCER MORTALITY2022